EQUITY RESEARCH

Influential opinions and insights on companies

Our equity analysts ask the right questions, dig deeper for answers and find details others miss. Our research division covers key Canadian healthcare companies to understand how they operate, recognize their relative strengths and weaknesses, and determine the impact of clinical and commercial developments and competitive events.

Specialized equity research that gets attention

Our analysts make influential buy, sell and hold recommendations in healthcare and biotechnology, gather industry knowledge, and provide insightful market intelligence to help guide our investor clients.

Charting what’s new in biotech: Bloom Burton’s Top Ideas; Healthcare Sector Review/Preview

Our Top Ideas; Healthcare Sector Review/Preview report, published annually, is essential reading for institutional investors to track historical sector performance and glean insight for the upcoming year, including milestones that could impact share performance.

Distribution of healthcare research

Bloom Burton’s research products are disseminated simultaneously to all our customers who are authorized to receive them. Request to be added to Bloom Burton’s equity research distribution list. Email Brian Bloom at bbloom@bloomburton.com.

Research Coverage

  • Aurinia Pharmaceuticals (TSX: AUP, NASDAQ: AUPH)
  • BELLUS Health (TSX:BLU, NASDAQ: BLU)
  • BioSyent Inc. (TSX-V: RX)
  • Cipher Pharmaceuticals (TSX: CPH)
  • CRH Medical (TSX: CRH, NASDAQ: CHRM)
  • ESSA Pharma. (TSX:EPI, NASDAQ: EPIX)
  • Greenbrook TMS Inc. (TSX: GTMS)
  • Hamilton Thorne (TSX-V:HTL)
  • HLS Therapeutics (TSX:HLS)
  • Knight Therapeutics (TSX:GUD)
  • Liminal Biosciences (TSX: LMNL, NASDAQ: LMNL)
  • Medexus Pharmaceuticals (TSX-V: MDP)
  • Medicenna Therapeutics Corp. (TSX:MDNA)
  • Mimi’s Rock (TSX-V: MIMI)
  • Newtopia (TSX-V: NEWU)
  • Nuvo Pharmaceuticals Inc. (TSX: NRI)
  • Trillium Therapeutics (TSX: TRIL, NASDAQ: TRIL)
  • Xenon Pharmaceuticals (NASDAQ: XENE)
  • Zymeworks Inc. (NYSE: ZYME)

 

For more information on our equity research services, please contact:

David Martin
dmartin@bloomburton.com
416-642-8865